Tardive dyskinesia is caused by maladaptive synaptic plasticity: A hypothesis

Movement Disorders

Volumn 27, Issue 10, 2012, Pages 1205-1215

  Teo, James T ^a   Edwards, Mark J ^a   Bhatia, Kailash ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotic; Catatonia; Genetics; Plasticity; Tardive dyskinesia

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR BETA2; 4 AMINOBUTYRIC ACID A RECEPTOR GAMMA3; 4 AMINOBUTYRIC ACID CARRIER; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ARRESTIN 2; BRAIN DERIVED NEUROTROPHIC FACTOR; CANNABINOID RECEPTOR; CATECHOL METHYLTRANSFERASE; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTATHIONE TRANSFERASE; GLYCOGEN SYNTHASE KINASE 3BETA; HALOPERIDOL; MANGANESE SUPEROXIDE DISMUTASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; PROTEOHEPARAN SULFATE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RGS PROTEIN; RGS9 PROTEIN; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SLC6A11 PROTEIN; TRANSCRIPTION FACTOR GLI2; UNCLASSIFIED DRUG;

ARTICLE; BRAIN NERVE CELL; CLINICAL FEATURE; CONCEPTUAL FRAMEWORK; CORPUS STRIATUM; DRUG RECEPTOR BINDING; EXCITOTOXICITY; GABAERGIC SYSTEM; GENETIC ASSOCIATION; HEPARAN SULFATE PROTEOGLYCAN 2; HUMAN; HYPERSENSITIVITY; INTERNEURON; MALADAPTIVE SYNAPTIC PLASTICITY; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TARDIVE DYSKINESIA;

ADAPTATION, PHYSIOLOGICAL; ANTIPSYCHOTIC AGENTS; CORPUS STRIATUM; EXCITATORY AMINO ACID AGENTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; MOVEMENT DISORDERS; N-METHYLASPARTATE; NEURONAL PLASTICITY; OXIDATIVE STRESS; SYNAPSES;

EID: 84866291484     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25107     Document Type: Article

References (240)

1. Delay J, Deniker P, Fourment J, Green A, Ropert M. [New types of neurological complications caused by a new neuroleptic drug, prochlorperazine]. [Article in French]. Ann Med Psychol (Paris) 1957; 115: 510-515.
2. Schonecker M. [Paroxysmal dyskinesia as the effect of megaphen]. [Article in German]. Nervenarzt 1957; 28: 550-553.
3. Hunter R, Earl CJ, Thronicroft S. An apparently irreversible syndrome of abnormal movements following phenothiazine medication. Proc R Soc Med 1964; 57: 758-762.
4. Sigwald J, Bouttier D, Raymondeaud C, Piot C. [4 Cases of facio-bucco-linguo-masticatory dyskinesis of prolonged development following treatment with neuroleptics]. [Article in French]. Rev Neurol (Paris) 1959; 100: 751-755.
5. Baldessarini RJ, Tarsy D. Mechanisms underlying tardive dyskinesia. Res Publ Assoc Res Nerv Ment Dis 1976; 55: 433-446.
6. Crane GE. Tardive dyskinesia in patients treated with major neuroleptics: a review of the literature. Am J Psychiatry 1968; 124:Suppl: 40-48.
7. Crane GE. Is tardive dyskinesia a drug effect? Am J Psychiatry 1973; 130: 1043-1044.
8. Marsden CD. The neuropharmacology of abnormal involuntary movement disorders (the dyskinesias). Mod Trends Neurol 1975; 6: 141-166.
9. Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982; 32: 1335-1346.
10. Burke RE, Kang UJ, Jankovic J, Miller LG, Fahn S. Tardive akathisia: an analysis of clinical features and response to open therapeutic trials. Mov Disord 1989; 4: 157-175.
11. Fernandez HH, Krupp B, Friedman JH. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up. Neurology 2001; 56: 805-807.
12. Tenback DE, van Harten PN, Slooff CJ, van Os J. Incidence and persistence of tardive dyskinesia and extrapyramidal symptoms in schizophrenia. J Psychopharmacol 2009; 24: 1031-1035.
13. Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain 1998; 121: 2053-2066.
14. Gimenez-Roldan S, Mateo D, Bartolome P. Tardive dystonia and severe tardive dyskinesia. A comparison of risk factors and prognosis. Acta Psychiatr Scand 1985; 71: 488-494.
15. Oosthuizen PP, Emsley RA, Maritz JS, Turner JA, Keyter N. Incidence of tardive dyskinesia in first-episode psychosis patients treated with low-dose haloperidol. J Clin Psychiatry 2003; 64: 1075-1080.
16. Halliday J, Farrington S, Macdonald S, MacEwan T, Sharkey V, McCreadie R. Nithsdale Schizophrenia Surveys 23: movement disorders. 20-year review. Br J Psychiatry 2002; 181: 422-427.
17. Caligiuri MR, Jeste DV, Lacro JP. Antipsychotic-Induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging 2000; 17: 363-384.
18. Saltz BL, Woerner MG, Kane JM, et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991; 266: 2402-2406.
19. Tenback DE, van Harten PN, van Os J. Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis. Mov Disord 2009; 24: 2309-2315.
20. Woerner MG, Alvir JM, Saltz BL, Lieberman JA, Kane JM. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 1998; 155: 1521-1528.
21. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982; 39: 473-481.
22. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. Psychopharmacology Suppl 1985; 2: 72-78.
23. Klawans HL, Jr., McKendall RR. Observations on the effect of levodopa on tardive lingual-facial-buccal dyskinesia. J Neurol Sci 1971; 14: 189-192.
24. Klawans HL, Jr., Rubovits R. An experimental model of tardive dyskinesia. J Neural Transm 1972; 33: 235-246.
25. Marsden CD, Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 1980; 10: 55-72.
26. Calabresi P, De Murtas M, Mercuri NB, Bernardi G. Chronic neuroleptic treatment: D2 dopamine receptor supersensitivity and striatal glutamatergic transmission. Ann Neurol 1992; 31: 366-373.
27. Ananth J. Current psychopathological theories of tardive dyskinesia and their implications for future research. Neuropsychobiology 1982; 8: 210-222.
28. Peralta V, Campos MS, De Jalon EG, Cuesta MJ. Motor behavior abnormalities in drug-naïve patients with schizophrenia spectrum disorders. Mov Disord 2010; 25: 1068-1076.
29. Peralta V, Cuesta MJ. The effect of antipsychotic medication on neuromotor abnormalities in neuroleptic-naïve nonaffective psychotic patients: a naturalistic study with haloperidol, risperidone, or olanzapine. Prim Care Companion J Clin Psychiatry 2010; 12(2).
30. Rogue P, Hanauer A, Zwiller J, Malviya AN, Vincendon G. Up-regulation of dopamine D2 receptor mRNA in rat striatum by chronic neuroleptic treatment. Eur J Pharmacol 1991; 207: 165-168.
31. Turrone P, Remington G, Kapur S, Nobrega JN. The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. Psychopharmacology (Berl) 2003; 165: 166-171.
32. Casey DE. Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 2004; 65(Suppl 9): 25-28.
33. Silvestri S, Seeman MV, Negrete JC, et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 2000; 152: 174-180.
34. Adler CM, Malhotra AK, Elman I, Pickar D, Breier A. Amphetamine-induced dopamine release and post-synaptic specific binding in patients with mild tardive dyskinesia. Neuropsychopharmacology 2002; 26: 295-300.
35. Andersson U, Eckernas SA, Hartvig P, Ulin J, Langstrom B, Haggstrom JE. Striatal binding of 11C-NMSP studied with positron emission tomography in patients with persistent tardive dyskinesia: no evidence for altered dopamine D2 receptor binding. J Neural Transm Gen Sect 1990; 79: 215-226.
36. Blin J, Baron JC, Cambon H, et al. Striatal dopamine D2 receptors in tardive dyskinesia: PET study. J Neurol Neurosurg Psychiatry 1989; 52: 1248-1252.
37. Crow TJ, Cross AJ, Johnstone EC, Owen F, Owens DG, Waddington JL. Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors? J Clin Psychopharmacol 1982; 2: 336-340.
38. Andreassen OA, Jorgensen HA. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol 2000; 61: 525-541.
39. Burger M, Fachinetto R, Calegari L, Paixao MW, Braga AL, Rocha JB. Effects of age on reserpine-induced orofacial dyskinesia and possible protection of diphenyl diselenide. Brain Res Bull 2004; 64: 339-345.
40. Miller R, Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis, and refractory schizophrenia. Biol Psychiatry 1993; 34: 713-738.
41. Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003; 17: 47-62.
42. Pall HS, Williams AC, Blake DR. Iron, akathisia, and antipsychotic drugs. Lancet 1986; 2: 1469.
43. Parikh V, Khan MM, Mahadik SP. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 2003; 37: 43-51.
44. Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 1998; 155: 1207-1213.
45. Adler LA, Rotrosen J, Edson R, et al. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry 1999; 56: 836-841.
46. Andreassen OA, Weber C, Jorgensen HA. Coenzyme Q10 does not prevent oral dyskinesias induced by long-term haloperidol treatment of rats. Pharmacol Biochem Behav 1999; 64: 637-642.
47. Lohr JB, Caligiuri MP. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry 1996; 57: 167-173.
48. Soares KV, McGrath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2001;(4): CD000209.
49. Libov I, Miodownik C, Bersudsky Y, Dwolatzky T, Lerner V. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry 2007; 68: 1031-1037.
50. Adler LA, Peselow E, Rotrosen J, et al. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry 1993; 150: 1405-1407.
51. Lerner V, Kaptsan A, Miodownik C, Kotler M. Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study. Clin Neuropharmacol 1999; 22: 241-243.
52. Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001; 158: 1511-1514.
53. Zhang WF, Tan YL, Zhang XY, Chan RC, Wu HR, Zhou DF. Extract of ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010; 72: 615-621.
54. Zhang XY, Zhou DF, Cao LY, Xu CQ, Chen DC, Wu GY. The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial. J Clin Psychopharmacol 2004; 24: 83-86.
55. Frazier JA, Giedd JN, Kaysen D, et al. Childhood-onset schizophrenia: brain MRI rescan after 2 years of clozapine maintenance treatment. Am J Psychiatry 1996; 153: 564-566.
56. Chakos MH, Lieberman JA, Alvir J, Bilder R, Ashtari M. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet 1995; 345: 456-457.
57. Corson PW, Nopoulos P, Miller DD, Arndt S, Andreasen NC. Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. Am J Psychiatry 1999; 156: 1200-1204.
58. Gur RE, Maany V, Mozley PD, Swanson C, Bilker W, Gur RC. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am J Psychiatry 1998; 155: 1711-1717.
59. Lang DJ, Kopala LC, Vandorpe RA, et al. An MRI study of basal ganglia volumes in first-episode schizophrenia patients treated with risperidone. Am J Psychiatry 2001; 158: 625-631.
60. Kuznetsov Y, Khiat A, Blanchet PJ, Boulanger Y. Proton magnetic resonance spectroscopy study of dyskinesia patients. Mov Disord 2007; 22: 957-962.
61. Ando K, Takei N, Matsumoto H, Iyo M, Isoda H, Mori N. Neural damage in the lenticular nucleus linked with tardive dyskinesia in schizophrenia: a preliminary study using proton magnetic resonance spectroscopy. Schizophr Res 2002; 57: 273-279.
62. Andreassen OA, Finsen B, Ostergaard K, Sorensen JC, West MJ, Jorgensen HA. The relationship between oral dyskinesias produced by long-term haloperidol treatment, the density of striatal preproenkephalin messenger RNA and enkephalin peptide, and the number of striatal neurons expressing preproenkephalin messenger RNA in rats. Neuroscience 1999; 88: 27-35.
63. Gunne LM, Andren PE. An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia. Clin Neuropharmacol 1993; 16: 90-95.
64. Tamminga CA, Woerner MG. Clinical course and cellular pathology of tardive dyskinesia. In: Davis KL, American College of Neuropsychopharmacology, eds. Neuropsychopharmacology: The Fifth Generation of Progress: An official publication of the American College of Neuropsychopharmacology. Philadelphia, PA: Lippincott Williams & Wilkins; 2002: 1831-1841.
65. Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction. Can J Psychiatry 2005; 50: 541-547.
66. Sachdev P, Saharov T, Cathcart S. The preventative role of antioxidants (selegiline and vitamin E) in a rat model of tardive dyskinesia. Biol Psychiatry 1999; 46: 1672-1681.
67. Tayoshi S, Nakataki M, Sumitani S, et al. GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study. Schizophr Res 2009; 117: 83-91.
68. Mallet N, Le Moine C, Charpier S, Gonon F. Feedforward inhibition of projection neurons by fast-spiking GABA interneurons in the rat striatum in vivo. J Neurosci 2005; 25: 3857-3869.
69. Gittis AH, Nelson AB, Thwin MT, Palop JJ, Kreitzer AC. Distinct roles of GABAergic interneurons in the regulation of striatal output pathways. J Neurosci 2010; 30: 2223-2234.
70. Gage GJ, Stoetzner CR, Wiltschko AB, Berke JD. Selective activation of striatal fast-spiking interneurons during choice execution. Neuron 2010; 67: 466-479.
71. Gittis AH, Leventhal DK, Fensterheim BA, Pettibone JR, Berke JD, Kreitzer AC. Selective inhibition of striatal fast-spiking interneurons causes dyskinesias. J Neurosci 2011; 31: 15727-15731.
72. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006; 21: 589-598.
73. Friedman JH. Historical perspective on movement disorders. J Clin Psychiatry 2004; 65(Suppl 9): 3-8.
74. Arato M, O'Connor R, Meltzer HY. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80, and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002; 17: 207-215.
75. Beasley CM, Dellva MA, Tamura RN, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999; 174: 23-30.
76. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346: 16-22.
77. Dolder CR, Jeste DV. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biol Psychiatry 2003; 53: 1142-1145.
78. Haro JM, Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs 2006; 20: 293-301.
79. Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 2008; 193: 279-288.
80. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-1087.
81. Woods SW, Morgenstern H, Saksa JR, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 2010; 71: 463-474.
82. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371: 1085-1097.
83. Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 2009; 39: 1591-1602.
84. Strous RD, Kupchik M, Roitman S, et al. Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study. Hum Psychopharmacol 2006; 21: 235-243.
85. Novick D, Haro JM, Bertsch J, Haddad PM. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol 2010; 30: 531-540.
86. Remington G. Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr Opin Psychiatry 2007; 20: 131-137.
87. Strange PG. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 2001; 53: 119-133.
88. Inoue A, Miki S, Seto M, et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 1997; 321: 105-111.
89. Natesan S, Reckless GE, Nobrega JN, Fletcher PJ, Kapur S. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 2006; 31: 1854-1863.
90. Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003; 28: 1400-1411.
91. Tamminga CA, Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord 2002; 1: 141-147.
92. Evcimen YA, Evcimen H, Holland J. Aripiprazole-induced tardive dyskinesia: the role of tamoxifen. Am J Psychiatry 2007; 164: 1436-1437.
93. Pena MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord 2010; 26: 147-152.
94. Schwartz T, Raza S. Aripiprazole (abilify) and tardive dyskinesia. P T 2008; 33: 32-34.
95. Andreassen OA, MacEwan T, Gulbrandsen AK, McCreadie RG, Steen VM. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology (Berl) 1997; 131: 174-179.
96. Basile VS, Ozdemir V, Masellis M, et al. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 2000; 5: 410-417.
97. Fu Y, Fan CH, Deng HH, et al. Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Acta Pharmacol Sin 2006; 27: 328-332.
98. Tiwari AK, Deshpande SN, Rao AR, et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmacogenomics J 2005; 5: 60-69.
99. Chen CH, Wei FC, Koong FJ, Hsiao KJ. Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry 1997; 41: 827-829.
100. Zai CC, Hwang RW, De Luca V, et al. Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int J Neuropsychopharmacol 2007; 10: 639-651.
101. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2, and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol Psychiatry 2008; 13: 544-556.
102. Koning JP, Vehof J, Burger H, et al.; Genetic Risk and Outcome in Psychosis (GROUP) investigators. Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients. Psychopharmacology (Berl) 2012; 219: 727-736.
103. Basile VS, Masellis M, Badri F, et al. Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology 1999; 21: 17-27.
104. Liao DL, Yeh YC, Chen HM, Chen H, Hong CJ, Tsai SJ. Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2001; 44: 95-98.
105. Lerer B, Segman RH, Fangerau H, et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002; 27: 105-119.
106. Bakker PR, van Harten PN, van Os J. Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. Schizophr Res 2006; 83: 185-192.
107. Zai CC, Tiwari AK, De Luca V, et al. Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. Eur Neuropsychopharmacol 2009; 19: 317-328.
108. Mo GH, Lai IC, Wang YC, et al. Support for an association of the C939T polymorphism in the human DRD2 gene with tardive dyskinesia in schizophrenia. Schizophr Res 2007; 97: 302-304.
109. Zai CC, Tiwari AK, Basile V, et al. Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. Pharmacogenomics J 2009; 9: 168-174.
110. Srivastava V, Varma PG, Prasad S, et al. Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet Genomics 2006; 16: 111-117.
111. Inada T, Koga M, Ishiguro H, et al. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet Genomics 2008; 18: 317-323.
112. Tan EC, Chong SA, Mahendran R, Dong F, Tan CH. Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor. Biol Psychiatry 2001; 50: 144-147.
113. Segman RH, Heresco-Levy U, Finkel B, et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 2001; 6: 225-229.
114. Lerer B, Segman RH, Tan EC, et al. Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol 2005; 8: 411-425.
115. Wilffert B, Al Hadithy AF, Sing VJ, et al. The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Curacao extrapyramidal syndromes study IX. J Psychopharmacol 2009; 23: 652-659.
116. Segman RH, Heresco-Levy U, Finkel B, et al. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology (Berl) 2000; 152: 408-413.
117. Gunes A, Dahl ML, Spina E, Scordo MG. Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. Eur J Clin Pharmacol 2008; 64: 477-482.
118. Tiwari AK, Zai CC, Likhodi O, et al. Association study of Cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia. Pharmacogenomics J 2012; 12: 260-266.
119. Liou YJ, Wang YC, Chen JY, et al. Association analysis of polymorphisms in the N-methyl-D-aspartate (NMDA) receptor subunit 2B (GRIN2B) gene and tardive dyskinesia in schizophrenia. Psychiatry Res 2007; 153: 271-275.
120. Liou YJ, Liao DL, Chen JY, et al. Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients. Neuromolecular Med 2004; 5: 243-251.
121. Xu MQ, St Clair D, Feng GY, et al. BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population. Pharmacogenet Genomics 2008; 18: 449-457.
122. Park SW, Lee JG, Kong BG, et al. Genetic association of BDNF val66met and GSK-3beta-50T/C polymorphisms with tardive dyskinesia. Psychiatry Clin Neurosci 2009; 63: 433-439.
123. Hori H, Ohmori O, Shinkai T, et al. Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacology 2000; 23: 170-177.
124. Kang SG, Choi JE, An H, et al. Manganese superoxide dismutase gene Ala-9Val polymorphism might be related to the severity of abnormal involuntary movements in Korean schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1844-1847.
125. Liou YJ, Lai IC, Lin MW, et al. Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia. Pharmacogenet Genomics 2006; 16: 151-157.
126. Pae CU, Yu HS, Kim JJ, et al. Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia. Int J Neuropsychopharmacol 2004; 7: 495-500.
127. Liou YJ, Wang YC, Lin CC, et al. Association analysis of NAD(P)Hratioquinone oxidoreductase (NQO1) Pro187Ser genetic polymorphism and tardive dyskinesia in patients with schizophrenia in Taiwan. Int J Neuropsychopharmacol 2005; 8: 483-486.
128. de Leon J, Susce MT, Pan RM, Koch WH, Wedlund PJ. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol 2005; 25: 448-456.
129. Souza RP, Remington G, Chowdhury NI, et al. Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians. Eur Neuropsychopharmacol 2010; 20: 688-694.
130. Greenbaum L, Alkelai A, Rigbi A, Kohn Y, Lerer B. Evidence for association of the GLI2 gene with tardive dyskinesia in patients with chronic schizophrenia. Mov Disord 2010; 25: 2809-2817.
131. Syu A, Ishiguro H, Inada T, et al. Association of the HSPG2 gene with neuroleptic-induced tardive dyskinesia. Neuropsychopharmacology 2010; 35: 1155-1164.
132. Greenbaum L, Alkelai A, Zozulinsky P, Kohn Y, Lerer B. Support for association of HSPG2 with tardive dyskinesia in Caucasian populations. Pharmacogenomics J 2011 Aug 2. doi: 10.1038/tpj.2011.32.
133. Liou YJ, Chen ML, Wang YC, et al. Analysis of genetic variations in the RGS9 gene and antipsychotic-induced tardive dyskinesia in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2009; 150B: 239-242.
134. Liou YJ, Wang YC, Chen JY, et al. The coding-synonymous polymorphism rs1045280 (Ser280Ser) in beta-arrestin 2 (ARRB2) gene is associated with tardive dyskinesia in Chinese patients with schizophrenia. Eur J Neurol 2008; 15: 1406-1408.
135. Kapitany T, Meszaros K, Lenzinger E, et al. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res 1998; 32: 101-106.
136. Ohmori O, Suzuki T, Kojima H, et al. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr Res 1998; 32: 107-113.
137. Crowley JJ, Kim Y, Szatkiewicz JP, et al. Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice. Mamm Genome 2012; 23: 322-335.
138. Bliss TV, Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol 1973; 232: 331-356.
139. Malenka RC, Bear MF. LTP and LTD: an embarrassment of riches. Neuron 2004; 44: 5-21.
140. Kreitzer AC, Malenka RC. Striatal plasticity and basal ganglia circuit function. Neuron 2008; 60: 543-554.
141. Lovinger DM. Neurotransmitter roles in synaptic modulation, plasticity, and learning in the dorsal striatum. Neuropharmacology 2010; 58: 951-961.
142. Calabresi P, Picconi B, Tozzi A, Di Filippo M. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 2007; 30: 211-219.
143. Cheeran B, Koch G, Stagg CJ, Baig F, Teo J. Transcranial magnetic stimulation: from neurophysiology to pharmacology, molecular biology and genomics. Neuroscientist 2010; 16: 210-221.
144. Huang YZ, Rothwell JC, Lu CS, Chuang WL, Chen RS. Abnormal bidirectional plasticity-like effects in Parkinson's disease. Brain 2011; 134: 2312-2320.
145. Kuo MF, Paulus W, Nitsche MA. Boosting focally-induced brain plasticity by dopamine. Cereb Cortex 2008; 18: 648-651.
146. Monte-Silva K, Liebetanz D, Grundey J, Paulus W, Nitsche MA. Dosage-dependent non-linear effect of L-dopa on human motor cortex plasticity. J Physiol 2010; 588: 3415-3424.
147. Morgante F, Espay AJ, Gunraj C, Lang AE, Chen R. Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain 2006; 129: 1059-1069.
148. Nitsche MA, Lampe C, Antal A, et al. Dopaminergic modulation of long-lasting direct current-induced cortical excitability changes in the human motor cortex. Eur J Neurosci 2006; 23: 1651-1657.
149. Teo JT, Terranova C, Swayne O, Greenwood RJ, Rothwell JC. Differing effects of intracortical circuits on plasticity. Exp Brain Res 2009; 193: 555-563.
150. Swayne OB, Teo JT, Greenwood RJ, Rothwell JC. The facilitatory effects of intermittent theta burst stimulation on corticospinal excitability are enhanced by nicotine. Clin Neurophysiol 2009; 120: 1610-1615.
151. Korchounov A, Ziemann U. Neuromodulatory neurotransmitters influence LTP-like plasticity in human cortex: a pharmaco-TMS study. Neuropsychopharmacology 2011; 36: 1894-1902.
152. Nitsche MA, Kuo MF, Grosch J, Bergner C, Monte-Silva K, Paulus W. D1-receptor impact on neuroplasticity in humans. J Neurosci 2009; 29: 2648-2653.
153. Monte-Silva K, Ruge D, Teo JT, Paulus W, Rothwell JC, Nitsche MA. D2 receptor block abolishes theta burst stimulation-induced neuroplasticity in the human motor cortex. Neuropsychopharmacology 2011; 36: 2097-2102.
154. Centonze D, Usiello A, Costa C, et al. Chronic haloperidol promotes corticostriatal long-term potentiation by targeting dopamine D2L receptors. J Neurosci 2004; 24: 8214-8222.
155. Kerns JM, Sierens DK, Kao LC, Klawans HL, Carvey PM. Synaptic plasticity in the rat striatum following chronic haloperidol treatment. Clin Neuropharmacol 1992; 15: 488-500.
156. Di Filippo M, Tozzi A, Picconi B, Ghiglieri V, Calabresi P. Plastic abnormalities in experimental Huntington's disease. Curr Opin Pharmacol 2007; 7: 106-111.
157. Picconi B, Passino E, Sgobio C, et al. Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons. Neurobiol Dis 2006; 22: 143-152.
158. Belujon P, Lodge DJ, Grace AA. Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment. Mov Disord 2010; 25: 1568-1576.
159. Errico F, Bonito-Oliva A, Bagetta V, et al. Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia. Exp Neurol 2011; 232: 240-250.
160. Calabresi P, Di Filippo M, Ghiglieri V, Tambasco N, Picconi B. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol 2010; 9: 1106-1117.
161. Picconi B, Centonze D, Hakansson K, et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 2003; 6: 501-506.
162. Quartarone A, Classen J, Morgante F, Rosenkranz K, Hallett M. Consensus paper: use of transcranial magnetic stimulation to probe motor cortex plasticity in dystonia and levodopa-induced dyskinesia. Brain Stimul 2009; 2: 108-117.
163. Orth M, Schippling S, Schneider SA, et al. Abnormal motor cortex plasticity in premanifest and very early manifest Huntington disease. J Neurol Neurosurg Psychiatry 2010; 81: 267-270.
164. Suppa A, Belvisi D, Bologna M, et al. Abnormal cortical and brain stem plasticity in Gilles de la Tourette syndrome. Mov Disord 2011; 26: 1703-1710.
165. Edwards MJ, Huang YZ, Mir P, Rothwell JC, Bhatia KP. Abnormalities in motor cortical plasticity differentiate manifesting and nonmanifesting DYT1 carriers. Mov Disord 2006; 21: 2181-2186.
166. Peterson DA, Sejnowski TJ, Poizner H. Convergent evidence for abnormal striatal synaptic plasticity in dystonia. Neurobiol Dis 2010; 37: 558-573.
167. Hasan A, Nitsche MA, Rein B, et al. Dysfunctional long-term potentiation-like plasticity in schizophrenia revealed by transcranial direct current stimulation. Behav Brain Res 2011; 224: 15-22.
168. Duncan GE, Zorn S, Lieberman JA. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia. Mol Psychiatry 1999; 4: 418-428.
169. Leveque JC, Macias W, Rajadhyaksha A, et al. Intracellular modulation of NMDA receptor function by antipsychotic drugs. J Neurosci 2000; 20: 4011-4020.
170. Arvanov VL, Liang X, Schwartz J, Grossman S, Wang RY. Clozapine and haloperidol modulate N-methyl-D-aspartate- and non-N-methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 1997; 283: 226-234.
171. Wittmann M, Marino MJ, Henze DA, Seabrook GR, Conn PJ. Clozapine potentiation of N-methyl-D-aspartate receptor currents in the nucleus accumbens: role of NR2B and protein kinase A/Src kinases. J Pharmacol Exp Ther 2005; 313: 594-603.
172. Banerjee SP, Zuck LG, Yablonsky-Alter E, Lidsky TI. Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia. Neuroreport 1995; 6: 2500-2504.
173. Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs 2011; 25: 859-885.
174. Abbruzzese G, Berardelli A. Sensorimotor integration in movement disorders. Mov Disord 2003; 18: 231-240.
175. Quartarone A, Rizzo V, Bagnato S, et al. Homeostatic-like plasticity of the primary motor hand area is impaired in focal hand dystonia. Brain 2005; 128: 1943-1950.
176. Quartarone A, Siebner HR, Rothwell JC. Task-specific hand dystonia: can too much plasticity be bad for you? Trends Neurosci 2006; 29: 192-199.
177. Quartarone A, Pisani A. Abnormal plasticity in dystonia: disruption of synaptic homeostasis. Neurobiol Dis 2011; 42: 162-170.
178. Farmer SF, Sheean GL, Mayston MJ, et al. Abnormal motor unit synchronization of antagonist muscles underlies pathological co-contraction in upper limb dystonia. Brain 1998; 121: 801-814.
179. Marsden CD. Is tardive dyskinesia a unique disorder? Psychopharmacology Suppl 1985; 2: 64-71.
180. Khot V, Wyatt RJ. Not all that moves is tardive dyskinesia. Am J Psychiatry 1991; 148: 661-666.
181. Casey DE. Spontaneous and tardive dyskinesias: clinical and laboratory studies. J Clin Psychiatry 1985; 46: 42-47.
182. Woerner MG, Kane JM, Lieberman JA, et al. The prevalence of tardive dyskinesia. J Clin Psychopharmacol 1991; 11: 34-42.
183. Waddington JL, O'Callaghan E, Buckley P, et al. Tardive dyskinesia in schizophrenia. Relationship to minor physical anomalies, frontal lobe dysfunction, and cerebral structure on magnetic resonance imaging. Br J Psychiatry 1995; 167: 41-44.
184. Koning JP, Tenback DE, van Os J, Aleman A, Kahn RS, van Harten PN. Dyskinesia and parkinsonism in antipsychotic-naïve patients with schizophrenia, first-degree relatives and healthy controls: a meta-analysis. Schizophr Bull 2009; 36: 723-731.
185. Fenton WS, Wyatt RJ, McGlashan TH. Risk factors for spontaneous dyskinesia in schizophrenia. Arch Gen Psychiatry 1994; 51: 643-650.
186. Honer WG, Kopala LC, Rabinowitz J. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness. J Psychopharmacol 2005; 19: 277-285.
187. Whitty PF, Owoeye O, Waddington JL. Neurological signs and involuntary movements in schizophrenia: intrinsic to and informative on systems pathobiology. Schizophr Bull 2009; 35: 415-424.
188. Kraepelin E, Barclay RM, Robertson GM. Dementia Præcox and Paraphrenia. Edinburgh, Scotland: E. & S. Livingstone; 1919.
189. Bleuler E. Dementia Praecox. New York, NY: International Universities Press; 1950.
190. Rogers D. The motor disorders of severe psychiatric illness: a conflict of paradigms. Br J Psychiatry 1985; 147: 221-232.
191. Peralta V, Campos MS, de Jalon EG, Cuesta MJ. DSM-IV catatonia signs and criteria in first-episode, drug-naive, psychotic patients: psychometric validity and response to antipsychotic medication. Schizophr Res 2010; 118: 168-175.
192. Ismail B, Cantor-Graae E, McNeil TF. Neurodevelopmental origins of tardivelike dyskinesia in schizophrenia patients and their siblings. Schizophr Bull 2001; 27: 629-641.
193. McCreadie RG, Thara R, Srinivasan TN, Padmavathi R. Spontaneous dyskinesia in first-degree relatives of chronically ill, never-treated people with schizophrenia. Br J Psychiatry 2003; 183: 45-49.
194. Dazzan P, Morgan KD, Chitnis X, et al. The structural brain correlates of neurological soft signs in healthy individuals. Cereb Cortex 2006; 16: 1225-1231.
195. Dazzan P, Morgan KD, Orr KG, et al. The structural brain correlates of neurological soft signs in AESOP first-episode psychoses study. Brain 2004; 127: 143-153.
196. Guy W, National Institute of Mental Health (U.S.). Psychopharmacology Research Branch. Division of Extramural Research Programs. ECDEU Assessment Manual for Psychopharmacology. Rev. 1976 ed. Rockville, MD: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
197. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11-19.
198. Dean CE, Russell JM, Kuskowski MA, Caligiuri MP, Nugent SM. Clinical rating scales and instruments: how do they compare in assessing abnormal, involuntary movements? J Clin Psychopharmacol 2004; 24: 298-304.
199. Taksh U. A critical review of rating scales in the assessment of movement disorders in schizophrenia. Curr Drug Targets 2006; 7: 1225-1229.
200. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986; 9: 357-381.
201. Gerardin E, Lehericy S, Pochon JB, et al. Foot, hand, face, and eye representation in the human striatum. Cereb Cortex 2003; 13: 162-169.
202. Howes OD, Montgomery AJ, Asselin MC, et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 2009; 66: 13-20.
203. Kegeles LS, Abi-Dargham A, Frankle WG, et al. Increased synaptic dopamine function in associative regions of the striatum in schizophrenia. Arch Gen Psychiatry 2010; 67: 231-239.
204. de la Fuente-Sandoval C, Leon-Ortiz P, Favila R, et al. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology 2011; 36: 1781-1791.
205. Sorg C, Manoliu A, Neufang S, et al. Increased intrinsic brain activity in the striatum reflects symptom dimensions in schizophrenia. Schizophr Bull 2012 Jan 12.
206. Ramsey AJ, Milenkovic M, Oliveira AF, et al. Impaired NMDA receptor transmission alters striatal synapses and DISC1 protein in an age-dependent manner. Proc Natl Acad Sci U S A 2010; 108: 5795-5800.
207. Ou X, Buckwalter G, McNeill TH, Walsh JP. Age-related change in short-term synaptic plasticity intrinsic to excitatory striatal synapses. Synapse 1997; 27: 57-68.
208. Wang Y. Differential effect of aging on synaptic plasticity in the ventral and dorsal striatum. Neurobiol Learn Mem 2008; 89: 70-75.
209. Fathi D, Ueki Y, Mima T, et al. Effects of aging on the human motor cortical plasticity studied by paired associative stimulation. Clin Neurophysiol 2010; 121: 90-93.
210. Murray RM, Lewis SW. Is schizophrenia a neurodevelopmental disorder? Br Med J (Clin Res Ed) 1987; 295: 681-682.
211. Weinberger DR. The pathogenesis of schizophrenia: a neurodevelopmental theory. In: Nasrallah RA, Weinberger DR, eds. Handbook of Schizophrenia: The Neurology of Schizophrenia v 1. Amsterdam: Elsevier Science Ltd.; 1986: 387-405.
212. Owen MJ, O'Donovan MC, Thapar A, Craddock N. Neurodevelopmental hypothesis of schizophrenia. Br J Psychiatry 2011; 198: 173-175.
213. Peralta V, de Jalon EG, Campos MS, Basterra V, Sanchez-Torres A, Cuesta MJ. Risk factors, pre-morbid functioning and episode correlates of neurological soft signs in drug-naïve patients with schizophrenia-spectrum disorders. Psychol Med 2010: 1-11.
214. Lips ES, Cornelisse LN, Toonen RF, et al. Functional gene group analysis identifies synaptic gene groups as risk factor for schizophrenia. Mol Psychiatry 2011 Sep 20. doi: 10.1038/mp.2011.117.
215. Kirov G, Pocklington AJ, Holmans P, et al. De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol Psychiatry 2012; 17: 142-153.
216. Deakin JF, Slater P, Simpson MD, et al. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem 1989; 52: 1781-1786.
217. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994; 51: 199-214.
218. Abi-Saab WM, D'Souza DC, Moghaddam B, Krystal JH. The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry 1998; 31(Suppl 2): 104-109.
219. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998; 281: 1349-1352.
220. Moghaddam B. Bringing order to the glutamate chaos in schizophrenia. Neuron 2003; 40: 881-884.
221. Pitcher GM, Kalia LV, Ng D, et al. Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors. Nat Med 2011; 17: 470-478.
222. Missitzi J, Gentner R, Geladas N, et al. Plasticity in human motor cortex is in part genetically determined. J Physiol 2011; 589: 297-306.
223. Fernandez-del-Olmo M, Cheeran BJ, Gomez-Garre P, et al. P20-16 The Rodil Project: understanding variability in the response to rTMS. Clin Neurophysiol 2010; 121: S223.
224. Andrews C, Aviles-Olmos I, Hariz M, Foltynie T. Which patients with dystonia benefit from deep brain stimulation? A metaregression of individual patient outcomes. J Neurol Neurosurg Psychiatry 2010; 81: 1383-1389.
225. Capelle HH, Blahak C, Schrader C, et al. Chronic deep brain stimulation in patients with tardive dystonia without a history of major psychosis. Mov Disord 2010; 25: 1477-1481.
226. Cohen OS, Hassin-Baer S, Spiegelmann R. Deep brain stimulation of the internal globus pallidus for refractory tardive dystonia. Parkinsonism Relat Disord 2007; 13: 541-544.
227. Damier P, Thobois S, Witjas T, et al. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiatry 2007; 64: 170-176.
228. Eltahawy HA, Feinstein A, Khan F, Saint-Cyr J, Lang AE, Lozano AM. Bilateral globus pallidus internus deep brain stimulation in tardive dyskinesia: a case report. Mov Disord 2004; 19: 969-972.
229. Franzini A, Marras C, Ferroli P, et al. Long-term high-frequency bilateral pallidal stimulation for neuroleptic-induced tardive dystonia. Report of two cases. J Neurosurg 2005; 102: 721-725.
230. Gruber D, Trottenberg T, Kivi A, et al. Long-term effects of pallidal deep brain stimulation in tardive dystonia. Neurology 2009; 73: 53-58.
231. Kefalopoulou Z, Paschali A, Markaki E, Vassilakos P, Ellul J, Constantoyannis C. A double-blind study on a patient with tardive dyskinesia treated with pallidal deep brain stimulation. Acta Neurol Scand 2009; 119: 269-273.
232. Sako W, Goto S, Shimazu H, et al. Bilateral deep brain stimulation of the globus pallidus internus in tardive dystonia. Mov Disord 2008; 23: 1929-1931.
233. Schrader C, Peschel T, Petermeyer M, Dengler R, Hellwig D. Unilateral deep brain stimulation of the internal globus pallidus alleviates tardive dyskinesia. Mov Disord 2004; 19: 583-585.
234. Trottenberg T, Volkmann J, Deuschl G, et al. Treatment of severe tardive dystonia with pallidal deep brain stimulation. Neurology 2005; 64: 344-346.
235. Ruge D, Cif L, Limousin P, et al. Shaping reversibility? Long-term deep brain stimulation in dystonia: the relationship between effects on electrophysiology and clinical symptoms. Brain 2011; 134: 2106-2115.
236. Andreassen OA, Aamo TO, Joorgensen HA. Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats. Br J Pharmacol 1996; 119: 751-757.
237. Konig P, Chwatal K, Havelec L, Riedl F, Schubert H, Schultes H. Amantadine versus biperiden: a double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders. Neuropsychobiology 1996; 33: 80-84.
238. Pappa S, Tsouli S, Apostolou G, Mavreas V, Konitsiotis S. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol 2010; 33: 271-275.
239. Shoham S, Mazeh H, Javitt DC, Heresco-Levy U. Glycine and D-cycloserine attenuate vacuous chewing movements in a rat model of tardive dyskinesia. Brain Res 2004; 1004: 142-147.
240. Nathan PJ, Cobb SR, Lu B, Bullmore ET, Davies CH. Studying synaptic plasticity in the human brain and opportunities for drug discovery. Curr Opin Pharmacol 2011; 11: 540-548.